IDENTIFICATION OF IMMUNODOMINANT EPITOPES IN ENVELOPE GLYCOPROTEIN OF HUMAN LYMPHOTROPIC-T VIRUS TYPE-II

被引:18
作者
LAL, RB
RUDOLPH, DL
KAPLAN, JE
HJELLE, B
LEVINE, PH
COLIGAN, JE
VISCIDI, RP
机构
[1] NCI,BETHESDA,MD 20817
[2] UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131
[3] NIAID,BIOL RESOURCES BRANCH,BETHESDA,MD 20894
[4] JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,ENDOWOOD DIV INFECT DIS,BALTIMORE,MD 21205
关键词
D O I
10.1016/0042-6822(92)90081-Y
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A series of synthetic peptides derived from the envelope glycoprotein of human T lymphotropic virus type II (HTLV-II) was used in an enzyme immunoassay to determine the immunodominant epitopes of envelope glycoprotein. Of the 11 synthetic peptides spanning the external glycoprotein of HTLV-II (gp52) and the 3 from the transmembrane protein (gp21), 3 peptides from gp52 (termed Env-2085-102. Env-20-209, and Env-20173-256) reacted with most of the polymerase chain reaction-confirmed HTLV-II specimens (83, 95, and 76%, respectively); all other peptides reacted minimally with these specimens. Env-20173-209 reacted with a greater percentage (91 to 100%) of specimens from different risk groups, including intravenous drug users (n = 30), North American Indians (n = 13), Guaymi Indians from Panama (n = 22), and routine U.S. blood donors (n = 34), when compared with Env-2085-102 (73 to 100%) or Env-203219-256 (68 to 83%). Furthermore, Env-2085-102 and Env-202172-209 had some reactivity (8-25%) with serafrom HTLV-I-infected individuals, whereas Env-20219-256 reacted with 58% of HTLV-I specimens. We conclude that peptides Env-2085-102 and Env-202173-209 represent the type-specific immunodominant epitopes of HTLV-II external glycoprotein. © 1992.
引用
收藏
页码:274 / 279
页数:6
相关论文
共 32 条
[1]   ANTIBODY REACTIVITY TO DIFFERENT REGIONS OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-1 GP61 IN INFECTED PEOPLE [J].
CHEN, YMA ;
LEE, TH ;
SAMUEL, KP ;
OKAYAMA, A ;
TACHIBANA, N ;
MIYOSHI, I ;
PAPAS, TS ;
ESSEX, M .
JOURNAL OF VIROLOGY, 1989, 63 (11) :4952-4957
[2]   TYPE-SPECIFIC ANTIGENS FOR SEROLOGICAL DISCRIMINATION OF HTLV-I AND HTLV-II INFECTION [J].
CHEN, YMA ;
LEE, TH ;
WIKTOR, SZ ;
SHAW, GM ;
MURPHY, EL ;
BLATTNER, WA ;
ESSEX, M .
LANCET, 1990, 336 (8724) :1153-1155
[3]  
HENEINE W, 1991, NEW ENGL J MED, V324, P565, DOI 10.1056/NEJM199102213240815
[4]   INCIDENCE OF HAIRY-CELL LEUKEMIA, MYCOSIS-FUNGOIDES, AND CHRONIC LYMPHOCYTIC-LEUKEMIA IN 1ST KNOWN HTLV-II-ENDEMIC POPULATION [J].
HJELLE, B ;
MILLS, R ;
SWENSON, S ;
MERTZ, G ;
KEY, C ;
ALLEN, S .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (03) :435-440
[5]  
HJELLE B, 1990, BLOOD, V76, P450
[6]   IDENTIFICATION OF TYPE-SPECIFIC LINEAR EPITOPES IN THE GLYCOPROTEINS GP46 AND GP21 OF HUMAN T-CELL LEUKEMIA VIRUSES TYPE-I AND TYPE-II USING SYNTHETIC PEPTIDES [J].
HORAL, P ;
HALL, WW ;
SVENNERHOLM, B ;
LYCKE, J ;
JEANSSON, S ;
RYMO, L ;
KAPLAN, MH ;
VAHLNE, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (13) :5754-5758
[7]  
JACOBSON S, 1991, J IMMUNOL, V146, P1155
[8]  
JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181
[9]   A NEW SUBTYPE OF HUMAN T-CELL LEUKEMIA-VIRUS (HTLV-II) ASSOCIATED WITH A T-CELL VARIANT OF HAIRY-CELL LEUKEMIA [J].
KALYANARAMAN, VS ;
SARNGADHARAN, MG ;
ROBERTGUROFF, M ;
MIYOSHI, I ;
BLAYNEY, D ;
GOLDE, D ;
GALLO, RC .
SCIENCE, 1982, 218 (4572) :571-573
[10]  
KURATA A, 1989, J IMMUNOL, V143, P2024